Biotech Values

[DewDiligence]

AZN’s checkpoint inhibitor, Durvalumab, on partial FDA clinical hold (no new enrollment) in H&N cancer trials:

http://endpts.com/breaking-fda-slaps-a-partial-hold-on-one-of-astrazenecas-crucial-durvalumab-programs/

Following the recent update on clinicaltrials.gov, AstraZeneca confirms that the US FDA has placed a partial clinical hold on the enrolment of new patients with head and neck squamous cell carcinoma (HNSCC) in clinical trials of durvalumab as monotherapy and in combination with tremelimumab or other potential medicines. All trials are continuing with existing patients.

ADXS has a combination trial with AZN in H&N cancer, so the above may be the cause of some recent weakness in ADXS' stock.